Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADA 2020: Medtronic Explains Strategy To Return Growth To Diabetes Business

Executive Summary

Medtronic will launch its next-generation MiniMed 780G insulin pump while continuing to develop complementary technologies to close the competitive gap with its rivals in the diabetes market.

You may also be interested in...



Medtronic Claims Share Gains In Cardiovascular And Neurostim

The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.

Medtronic Cardiovascular Chief Coyle To Lead iRhythm

Sean Salmon, the head of Medtronic’s diabetes business, will take over the leadership of the company’s cardiovascular business effective 1 January.

Medtronic Initiates Restructuring Program To Save Up To $475M Annually

The medtech giant will simplify its organizational structure, consolidate operations and give more autonomy to its individual operating units.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel